This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.

VENCLYXTO CLL PRESCRIBING INFORMATION

VENCLYXTO GB SUMMARY OF PRODUCT CHARACTERISTICS

VENCLYXTO NI SUMMARY OF PRODUCT CHARACTERISTICS

UK-VNCCLL-230491. Date of preparation: February 2024.

FRONTIERS is a programme of AbbVie promotional events and resources for UK HCPs involved in the management of haematological malignancies.

FRONTIERS comprises a series of in-person, CPD-accredited meetings with agendas devised by an expert clinical steering committee, plus regular online events and on-demand resources providing data updates, congress updates, practice pointers, and expert insights for UK HCPs.

ON-DEMAND RESOURCES

EVENTS

An overview of the evolving front-line treatment landscape in CLL

Dr Talha Munir reviews the datasets for both fixed-duration and continuous therapy options for treatment-naïve patients and offers insights on treatment decision-making in line with patients’ profiles and preferences.

An overview of the evolving front-line treatment landscape in CLL

UK-VNCCLL-240421. Date of Preparation: November 2024

Capacity Innovation – Patient initiated follow-up in Mersey and West Lancashire

Ruth Jackson, a Haematology Nurse Clinician, shares the challenges and benefits of establishing self-supported follow-up for patients with CLL and discusses the practicalities of using the online portal, My Medical Record.

Protecting our patients: Managing infection risk

Professor Paul Moss (Birmingham) describes immune suppression in patients with blood cancer and offers insights on providing protection and treatment for CLL patients at risk of infection.

CLL: Treatment guidelines and practical management

Watch Dr Dima El-Sharkawi (London) give an overview of the 2022 BSH guidelines on management of CLL and the place for fixed duration VENCLYXTO-based therapy.

Take V – Take five for fitness

Dr Piers Patten (London) raises the question, does fitness in CLL need a rethink?

Take V discussion – Take five for fitness

Listen to a five-way panel discussion on rethinking fitness in CLL. Chair – Dr Piers Patten. Panel – Dr Dima El-Sharkawi, Dr Ben Kennedy, Dr Tal Munir and Dr Renata Walewska.

Patient Initiated Follow Up for patients with CLL in Southampton

Claire Marsh, Cancer PIFU Project Lead University Hospital Southampton discusses the implementation of patient-initiated follow-up (PIFU) programmes for patients with CLL.

IGHV unmutated patient in CLL

Dr Lisa Lowry, Consultant Haematologist at the Somerset Foundation Trust considers the role of IGHV mutational status in the management of patients with CLL.

Prophylaxis in CLL

Jess Pealing, Lead Haematology Specialist Pharmacist at The Christie Hospital Manchester, discusses management of TLS and prophylactic steps recommended for CLL patients to help prevent the development of infectious complications.

Front line management for elderly patients in CLL

Dr Toby Eyre, Consultant Haematologist at the Oxford University Hospitals NHS Trust discusses the front-line management of elderly patients with CLL.

OnCaLL – conversations in CLL

Listen to Consultant Haematologist, Dr Nicolas Martinez-Calle, and Clinical Nurse Specialist, Helen Knight, discuss their clinical experiences relating to VEN+O patient management at Nottingham University Hospital.

UK-VNCCLL-230510. Date of preparation: June 2024.

Dr Walewska's ASH 2023 Highlights

Speaking during the ASH 2023 congress, Dr Renata Walewska (University Hospitals Dorset) expands on fixed-duration venetoclax therapy and treatment sequencing in CLL.

Fitness for VEN+O

Dr Nicolas Martinez-Calle (Nottingham University Hospital) describes how a pooled analysis of data from CLL-13 and CLL-14, presented at ASH 2023, highlights that VEN+O may offer a front-line option for CLL patients across different age and fitness groups.¹

Dr Patten's ASH 2023 Highlights

Dr Piers Patten (King's College London) describes how long-term follow-up data from CLL-13, a front-line study of VEN+O in CLL, is helping inform treatment decision-making.²

MURANO – Insights on treatment sequencing & VENCLYXTO retreatment

Insights from Dr Piers Patten (King's College London), speaking during ASH 2023, following data updates from the MURANO study relating to treatment sequencing.³

Fitness for VEN+O as a first-line therapy

Insights from a pooled analysis of CLL-13 and CLL-14 studies underscores the place for VEN+O in first-line management of CLL.¹

Evidence and arguments for fixed treatment duration in CLL

Dr Toby Eyre (Oxford) navigates the current evidence to provide a succinct summary and rationale for fixed-duration treatment approaches to CLL treatment.

CLL-13 overview

Dr Toby Eyre (Oxford) provides a bite-sized summary of the 3-year data from CLL-13 and what the findings mean for fit, previously untreated patients.⁴

Venetoclax CLL14 data – An overview of 6-year follow-up

Watch Dr Toby Eyre (Oxford) as he summarises the latest data read-outs from CLL-14, 5-years after the end of treatment in older, previously untreated patients with comorbidities.^5,6

Update on MURANO

In this video, Dr Toby Eyre (Oxford) discusses the final 7-year follow-up data from the MURANO study, a global, phase III open-label, randomised study of patients with R/R CLL being treated with VEN+R compared with bendamustine plus rituximab.⁷

References

Al-Sawaf O et al. Abstract and Poster 4639. ASH 2023.
Fürstenau M et al. Abstract 635. ASH 2023.
Harrup RA et al. Abstract and Poster 1898. ASH 2023.
Eichhorst B, et al. N Engl J Med 2023; 388:1739-1754 and suppl appendix.
Al-Sawaf O, et al. EHA 2023 Abstract S145 (and oral presentation).
Al-Sawaf O, et al. ICML 2023 Abstract 025 (and oral presentation).
Kater AP, et al. EHA 2023. Oral presentation S201.

UK-VNCCLL-230511 | Date of preparation: July 2024

ACP-led Ambulatory Service – Sharing our experience in Chesterfield

Haematology ACP Matthew Smith describes how he rose to the challenge to produce and lead an ambulatory service for patients with AML without an increase in funding or allocation of clinical space.

The CNS/Pharmacist Clinic in Cardiff

Discover the value of incorporating advanced practitioners into CLL and low-grade lymphoma consultant-led clinics from the perspective of Asjad Yousif, an Advanced Clinical Pharmacist, and Charlotte Bloodsworth, an Advanced Nurse Practitioner.

Experience with developing successful business cases

Glean valuable insight from haematologist Professor Adrian Bloor as he shares his 14 rules for developing business cases that persuade.

VENCLYXTO initiation & off-boarding in CLL

Watch specialist nurse Christina Kirby describe her experience and insights on on-boarding and off-boarding patients prescribed VEN+O at Basingstoke Hospital.

CLL – On-boarding patients with VENCLYXTO

Insights from Dr Nick Martinez-Calle (Nottingham) on treatment initiation for CLL patients starting VENCLYXTO-based therapy.

Holistic management in CLL

Dr Samir Agrawal, Senior Lecturer at the Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust, advocates patient-empowering, holistic treatment in CLL patients.

Dr Nimish Shah and Sharon March discuss how they manage first-line patients on VEN+O at Norfolk and Norwich University Hospital.

UK-VNCCLL-230512. Date of preparation: June 2024.

Front line CLL – the impact of genetic markers on treatment selection

Dr Othman Al-Sawaf of the German CLL Study Group provides insights on how genetic markers may impact the selection of front-line treatments for patients with CLL.

Titration high risk poster

A visual aid and guide to VENCLYXTO dosing and titration in patients at high risk for TLS.

Titration low/medium risk poster

A guide to VENCLYXTO dosing and titration in patients at low to medium risk for TLS.

Evidence and arguments for fixed duration treatment in CLL

Dr Toby Eyre (Oxford) navigates the current evidence to produce a succinct summary and rationale for fixed duration treatment approaches to CLL treatment.

CLL-decision-making in the relapsed/refractory setting

View an expert, case-based panel discussion, led by Dr Toby Eyre (Oxford), on the available evidence base from RCTs and real-world cohorts, for treatment of patients relapsing after CIT, after prior BCRi therapy or after venetoclax-based therapy. Featuring Dr Toby Eyre, Dr Dima El-Sharkawi, Dr Talha Munir, Dr Piers Patten & Dr Stella Williams.

An overview of the evolving front-line treatment landscape in CLL

Watch Dr Talha Munir (Leeds) present a succinct overview of the data supporting front-line treatment choices in CLL, including insights on fixed-duration and continuous treatment regimens, and the data regarding treatment choice according to TP53 and IGHV mutational status.

UK-VNCCLL-240475. Date of Preparation: November 2024

MODULE 1: Overview of haematology

A scene-setting learning summary on haematology.

MODULE 2: Overview of CLL

An overview on the disease landscape of CLL.

MODULE 3: Patient histories

Learning with case histories to support your CLL patient management.

MODULE 4: Venetoclax dosing

Practical pointers on using VENCLYXTO in practice, with a focus on dosing and administration.

MODULE 5: Tumour Lysis Syndrome management

A guide to prophylaxis, treatment and management of tumour lysis syndrome.

References

Al-Sawaf O et al. Abstract and Poster 4639. ASH 2023.
Fürstenau M et al. Abstract 635. ASH 2023.
Harrup RA et al. Abstract and Poster 1898. ASH 2023.

UK-VNCCLL-230514. Date of preparation: July 2024.

Looking for AML FRONTIERS? Access it here.

UK-VNCCLL-240482. Date of Preparation: November 2024

ON-DEMAND RESOURCES

EVENTS

Upcoming Events

FRONTIERS Live

FRONTIERS Live is a two-day, CPD accredited, in-person meeting in London for GB (England, Scotland and Wales) healthcare professionals. The meeting brings together a UK and international faculty of AML and CLL thought leaders to review emerging data, explore practical management and learn about approaches to service design.

It's never too early. Don't miss out.

Secure your place now

Looking for AML FRONTIERS? Access it here.

UK-VNCCLL-230518. Date of preparation: July 2024.

You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.

VENCLYXTO PRESCRIBING INFORMATION
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)

FRONTIERS is a programme of AbbVie promotional events and resources for UK HCPs involved in the management of haematological malignancies.

An overview of the evolving front-line treatment landscape in CLL

An overview of the evolving front-line treatment landscape in CLL

Upcoming Events

FRONTIERS Live

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome